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Abstract
Background: The predictive role of many cytokines has not been well defined in Acute Respiratory
Distress Syndrome (ARDS).
Methods: We measured prospectively IL-4, IL-6, IL-6 receptor, IL-8, and IL-10, in the serum and
bronchoalveolar lavage fluid (BALF) in 59 patients who were admitted to ICU in order to identify
predictive factors for the course and outcome of ARDS. The patients were divided into three groups:
those fulfilling the criteria for ARDS (n = 20, group A), those at risk for ARDS and developed ARDS within
48 hours (n = 12, group B), and those at risk for ARDS but never developed ARDS (n = 27, group C).
Results: An excellent negative predictive value for ARDS development was found for IL-6 in BALF and
serum (100% and 95%, respectively). IL-8 in BALF and IL-8 and IL-10 serum levels were higher in non-
survivors in all studied groups, and were associated with a high negative predictive value. A significant
correlation was found between IL-8 and APACHE score (r = 0.60, p < 0.0001). Similarly, IL-6 and IL-6r
were highly correlated with PaO2/FiO2 (r = -0.27, p < 0.05 and r = -0.55, p < 0.0001, respectively).
Conclusions: BALF and serum levels of the studied cytokines on admission may provide valuable
information for ARDS development in patients at risk, and outcome in patients either in ARDS or in at
risk for ARDS.
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Acute respiratory distress syndrome (ARDS) is character-
ized by respiratory failure of acute onset as a result of
acute lung injury (ALI) either directly or indirectly via the
blood. The main characteristics of the syndrome are dif-
fuse inflammation and increased microvascular permea-
bility that cause diffuses interstitial and alveolar oedema
and persistent refractory hypoxemia [1]. Although a vari-
ety of insults may lead to ARDS, a common pathway may
probably result in the lung damage [2-4]. A complex series
of inflammatory events have been recognized during the
development of ARDS but the exact sequence of the events
remains unclear. Leukocyte activation and free radical
release, proteases, arachidonic acid metabolites, inflam-
matory and anti-inflammatory cytokines results in the
increased alveolar-capillary membrane permeability [5-
7].
Cytokines are produced in the lung by local resident cells
such as alveolar macrophages, lung epithelial cells, and
fibroblasts or by cells such as neutrophils, lymphocytes,
monocytes and platelets as a response to local or systemic
injury [8-12]. Cytokines involved in the early phase of
inflammatory response, such as IL-1, IL-2, IL-6, IL-8,
[8,13,14] are secreted in response to injurious agents.
Inflammatory cytokines are of critical importance in the
pathophysiology of septic shock, a condition frequently
leading to ARDS [15]. It has been hypothesized that the
inability of lung to repair after ALI is due to a persisted
inflammatory stimulus [16].
Predictive levels of inflammatory cytokines (IL-1, IL-2, IL-
6, IL-8) for ARDS development in at risk patients have
been reported with controversial results [5,7,11,15,16].
Cut-off values above which ARDS development occurs in
at risk patients have been also reported for IL-4 and IL-10
[16]. Schutte et al [17] compared ARDS to pneumonia
and cardiogenic pulmonary oedema patients and found
higher IL-6 and IL-8 values in ARDS compared to remain-
ing populations. A systematic study of the role of all main
inflammatory cytokines at the same time in the pathogen-
esis and development of the ARDS has not been
undertaken.
The purpose of this study is to evaluate the role of inflam-
matory cytokines IL-4, IL-6, IL-6r, IL-8, and IL-10 in serum
and bronchoalveolar lavage (BALF) as possible prognostic
indicators for the development, severity, and outcome of
patients with ARDS or at risk for ARDS.
Methods
Patients
We studied prospectively 59 consecutive patients who
were admitted in our Intensive Care Units (ICU) (Table
1). The first group (group A) included 20 patients fulfill-
ing the criteria of ARDS [1]. All these patients were sup-
ported mechanically for their respiratory failure. The
second group (group B) included 12 patients on mechan-
ical respiratory support who had at least one condition
from those suggested by Fowler et al [2] as risk factors for
ARDS development. All patients in this group developed
ARDS within 48 hours. The third group (group C)
included 27 patients on high risk for ARDS development
who never developed ARDS (Table 1).
For patients' classification, the following criteria were
employed: 1. The ARDS criteria of the American-European
Consensus Conference on ARDS (1): a. acute onset, b.
bilateral chest radiographic infiltrates, c. pulmonary artery
occlusion pressure of ≤18 mm Hg, or no evidence of left
atrial hypertension, and d. impaired oxygenation regard-
less of the PEEP concentration, with a PaO2/FiO2 ratio of≤ 300 torr for ALI and ≤ 200 torr for ARDS. 2. The high-
risk criteria for ARDS development according to Fowler et
al [2]). 3. The criteria for pneumonia according to EPIC
study [18], and 4. The criteria for septic syndrome accord-
ing to Bone et al [19]. Acute Physiology and Chronic
Health Evaluation-II (APACHE II) scoring system was
used for grading the disease severity [20]).
The main clinical features of the patients are shown in
Table 1. The protocol was approved by the Ethics Com-
mittee of our institutions.
After admission to the ICU blood samples were obtained
from a central venous line within 2 hours. APACHE II
score and PaO2/FiO2 values were obtained at the time of
sample collection. The blood was collected in a
heparinized vacutainer tube and kept immediately at 4°C.
After centrifugation at 1500 g at 4°C, the plasma was kept
at -80°C until the measurement. Immediately after blood
collection BALF was obtained by fiberoptic bronchos-
copy. The fluid was filtered through nylon net to remove
the mucous secretions, and centrifuged at 500 g for 10
min to remove cells. The supernatant was kept in cryo-
tubes at -80°C in aliquots of 0.5 ml. The method of micro-
lavage was used as described previously [21]. The follow-
ing criteria were used for an acceptable sample: a. The pro-
cedure should be shorter than 1 min, while the time of
saline staying into the lungs should be less than 20 sec, b.
recovery of more than 50% of the saline used for the lav-
age, c. absence of obvious blood contamination in the
BALF, and d. the level of urea in the BALF should be more
than 0.4 mmol. The urea level was used as an index of
BALF dilution [21]. To check the accuracy of the method,
two subsequent lavages were taken in 8 patients and all
the studied parameters in the two samples did not differ
significantly.Page 2 of 9
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The assay method for cytokine measurement was the
same for blood and BALF samples. Determination of
plasma cytokines was done with solid phase enzyme-
linked immunosorbent assay (ELISA) methodology based
on the quantitative immunometric sandwich enzyme
immunoassay technique [22]. Reagents for the studied
cytokines were obtained from several sources (kits of R&D
systems, Inc. Minneapolis, MN, USA, for IL-6R, kits of
Genzyme Diagnostics, Cambridge, MA, USA for IL-8, IL-
10, and RIA kits of Amersham, Buckinghamshire, UK, for
IL-4, IL-6) were used according to manufacturer's instruc-
tions. Intra-assay and inter-assay reproducibility was
checked and found more than 90%. To calculate the dilu-
tion factor of the BALF, urea values in the plasma and
BALF were used because this low molecular weight sub-
stance is found to be in the body fluids at the same con-
centration as in the blood.
Statistical analysis
Data analysis was carried out using SPSS 8.0 statistical
software (SPSS Inc., Chicago, IL). Results are expressed as
mean ± 1SD, or median (range), unless otherwise indi-
cated. The Mann-Whitney non-parametric test was used to
compare the mean values of the cytokines in the blood
and BALF in the various groups. Receiver-operating char-
acteristic (ROC) correlation was used to find the optimal
cut-off values of the studied cytokines for ARDS develop-
ment in patient at risk and survival of the patient popula-
tion [23]. For tests of association, we calculated
Spearman's correlation coefficient. A p value <0.05 was
considered to be statistically significant.
Results
There was no significant difference in the mean age of the
patients among the three studied groups. Using APACHE-
II score to determine the severity of the disease, significant
difference between group A and group C (p = 0.04) and
group B and C (p = 0.045) was found, and not between
groups A and B (p = 0.06). The mean time of staying in the
ICU did not differ among the three groups.
Predictive capabilities of BALF mediators for onset of 
ARDS
The mean values (+/- SD) of the measured cytokines in
BALF and serum in the three studied patient groups are
shown in Table 2. A significant difference was found for
BALF IL-6r, which was higher in group A than in groups B
and C (p < 0.0001). Similarly, BALF IL-6 was higher in
groups A and B compared to C (p < 0.01).
Predictive capabilities of serum mediators for onset of 
ARDS
Serum levels of IL-4 were higher in group A compared to
groups B and C (p < 0.0001). Serum IL-6 was higher in
group B compared to group A and C (p < 0.05). Serum lev-
Table 1: Clinical features of the studied population on admission.
Group N Sex Age (yr) Diagnosis PaO2/FiO2 APACHE II
A 20 M = 14 53 ± 19 Trauma 9 121 ± 10 19.8 ± 1.4






B 12 M = 8 56 ± 20 Sepsis 3 239 ± 30 20.5 ± 1.3
F = 4 Pneumonia 4
Trauma 4
Pancreatitis 1
C 27 M = 21 49 ± 18 Sepsis 12 276 ± 16 16.0 ± 1.1*






D 33 M = 20 36 ± 16
F = 13
M = male, F = female, burns = >40% of the body surface. * p < 0.05 group A vs groups B and C.Page 3 of 9
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to group C (p < 0.0001) (Table 2). Predictive values for
ARDS development in at risk patients (groups B and C) for
BALF and serum IL-6 are shown in Table 3. IL-6 negative
predictive values for ARDS development were 100% and
95% for BALF cut off value of 195 pg/ml and serum cut off
value of 255 pg/ml, respectively.
Predictive capabilities of BALF mediators for survival of 
ARDS
Mean (SEM) values in BALF and serum of the studied
mediators in the survivors and non-survivors (groups
A+B+C) are shown in Table 4. BALF levels of IL-6, IL-6r
and IL-8 were significantly higher in those who did not
survive (p < 0.05, p < 0.05 and p < 0.0001, respectively).
Patients with ARDS (group A) who did not survive had
significantly higher BALF levels of IL-8 (p < 0.0001) and
significantly lower BALF levels of IL-10 (p < 0.001) (Table
5). Patients at risk (groups B and C) who did not survive
had significantly higher BALF levels of IL-8 (p < 0.0001)
(Table 6). IL-6, IL6-r and IL-8 BALF concentration cut off
predictive values for surviving patients are shown in Table
Table 2: Mean (+/-SD) BALF and serum levels of studied cytokines in the three groups of patients.
Group A (n = 20) Group B (n = 12) Group C (n = 27)
Cytokines (pg/mL) BALF Serum BALF Serum BALF Serum
IL-4 260 ± 181 158 ± 68 284 ± 119 95 ± 351 242 ± 147 83 ± 681
IL-6 538 ± 4322 388 ± 3243 1135 ± 13822 505 ± 217 318 ± 446 313 ± 3733
IL-6r 180 ± 52 30 ± 25 80 ± 374 34 ± 26 73 ± 224 39 ± 45
IL-8 480 ± 222 3525 ± 15235 492 ± 165 3543 ± 22655 467 ± 179 2553 ± 2824
IL-10 62 ± 24 117 ± 60 111 ± 98 177 ± 117 73 ± 50 118 ± 84
1p < 0.0001 versus group A, 2p < 0.01 versus group C. 3p < 0.05 versus group B. 4p < 0.0001 versus group A. 5p < 0.0001 versus group C.
Table 3: BALF and serum IL-6 predictive values for ARDS development in patients at risk (n = 39, groups B+C).
Criterion PPV NPV Sensitivity Specificity Prevalence 95% CI
BALF
IL-6, (pg/mL) >195 44 100 100 62 24 0.62–0.91
Serum
IL-6, (pg/mL) >255 44 95 88 65 24 0.60–0.90
PPV: positive predictive value, NPV: negative predictive value. CI: confidence interval
Table 4: Mean (SEM) BALF and serum levels of the measured cytokines in all patients (Groups A+B+C) according to survival.
BALF Serum
Cytokines (pg/ml) survivors (n = 30) non-survivors (n = 29) survivors (n = 30) non-survivors (n = 29)
IL-4 262 ± 188 247 ± 108 72 ± 51 154 ± 68***
IL-6 313 ± 427 743 ± 877* 218 ± 191 530 ± 389***
IL-6r 94 ± 52 129 ± 69* 18 ± 19 53 ± 42**
IL-8 340 ± 109 621 ± 144*** 1269 ± 830 4957 ± 1965***
IL-10 69 ± 37 82 ± 70 70 ± 16 188 ± 84***
* p < 0.05, ** p < 0.001, *** p < 0.0001 versus survivors group.Page 4 of 9
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died (p < 0.0001) (Table 8).
Predictive capabilities of serum mediators for survival of 
ARDS
Cytokine concentration cut off predictive values for sur-
viving patients are shown in Table 7. All studied
mediators were found at higher levels in the serum of
non-survivors (p < 0.001 to p < 0.0001). In patients at risk
(groups B and C) who did not survive all serum mediators
were significantly elevated (p < 0.001 to p < 0.0001)
(Table 6). Serum levels of all the studied molecules were
increased in all patients that did not survive (p < 0.05 to p
< 0.0001) (Table 8).
In survivors BALF/serum ratios were significantly higher
for IL-4, IL-8, IL-10 (p < 0.0001, p < 0.001 and p < 0.0001,
Table 5: Mean (SEM) BALF and serum levels of cytokines in ARDS patients according to survival (group A).
BALF Serum
Cytokines (pg/ml) Survivors (n = 6) Non-survivors (n = 14) Survivors (n = 6) Non-survivors (n = 14)
IL-4 352 ± 291 224 ± 115 155 ± 63 160 ± 73
IL-6 361 ± 238 606 ± 476 213 ± 140 455 ± 353
IL-6r 180 ± 38 180 ± 59 24 ± 24 31 ± 25
IL-8 218 ± 79 581 ± 167*** 2028 ± 700 4100 ± 1353*
IL-10 80 ± 12 55 ± 24** 63 ± 11 138 ± 58*
*p < 0.05, ** p < 0.001, *** p < 0.0001 versus survivors group.
Table 6: Mean (SEM) BALF and serum levels of cytokines in at risk patients who developed or not ARDS according to survival (Groups 
B and C).
BALF Serum
Cytokines (pg/ml) Survivors (n = 24) Non-survivors (n = 15) Survivors (n = 24) Non-survivors (n = 15)
IL-4 242 ± 160 271 ± 100 53 ± 21 147 ± 65***
IL-6 302 ± 463 890 ± 1178 219 ± 203 612 ± 423**
IL-6r 74 ± 29 74 ± 18 17 ± 18 77 ± 44***
IL-8 368 ± 96 664 ± 105*** 1097 ± 770 5885 ± 2151***
IL-10 67 ± 40 111 ± 91 72 ± 17 243 ± 74***
* p < 0.01, ** p < 0.001, *** p < 0.0001 versus survivors group.
Table 7: Predictive BALF and serum levels (pg/ml) for surviving patients of all groups (n = 59)
Criterion PPV NPV Sensitivity Specificity 95 % CI
BALF
IL-6 299 68 70 68 70 0.57–0.83
IL-6r 101 65 63 52 74 0.52–0.79
IL-8 481 96 90 88 96 0.85–0.99
Serum
IL-4 84 81 100 100 78 0.77–0.96
IL-6 160 69 94 96 59 0.69–0.92
IL-6r 18 76 78 76 78 0.66–0.89
IL-8 2340 92 96 96 93 0.90–0.99
IL-10 98 96 93 92 96 0.84–0.99
PPV: positive predictive value, NPV: negative predictive value, CI: confidence interval.Page 5 of 9
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BALF levels.
Correlations of the studied cytokines
Furthermore, the serum levels of all studied mediators
were significantly correlated to APACHE II score. Serum
IL-8 exhibited the strongest correlation with APACHE II
score (Figure 1). The level of IL-8 in the BALF were found
to be significantly correlated to APACHE II score (r = 0.60,
p < 0.0001).
PaO2/FiO2 ratio was significantly correlated to the BALF
levels of IL-6 and IL-6r (r = -0.27, p < 0.05; r = -0.55, p <
0.0001; respectively) (Figure 2) and to serum levels of IL-
4 (r = -0.36, p < 0.05).
Discussion
We designed this study in order to explore factors that
could have prognostic value for the development, the
severity, and the outcome of patients with ARDS and at
risk for ARDS.
Prediction of ARDS development
We observed that BALF levels of IL-6r were significantly
higher in group A than in groups B and C (p < 0.0001),
while no difference was observed in serum levels among
the three groups of patients. Interestingly, the BALF and
serum levels of cytokine IL-6 were significantly higher in
patients at risk who developed ARDS (group B) compared
to the other two groups. This observation differs from pre-
vious studies [24,25], probably reflecting the different
patient population from our study. However, our results
are in agreement with previous reports regarding the luck
of its prediction capacity for ARDS onset [25,26], since
both BALF and serum IL-6 levels, showed a low positive
predictive value according to the ROC analysis.
Table 8: Mean (SEM) BALF and serum levels of cytokines in at risk patients who did not develop ARDS (group C)
BALF Serum
Cytokines (pg/ml) Survivors (n = 19) Non-survivors (n = 8) Survivors (n = 19) Non-survivors (n = 8)
IL-4 242 ± 169 243 ± 69 51 ± 22 169 ± 78**
IL-6 297 ± 497 374 ± 285 199 ± 197 620 ± 559*
IL-6r 70 ± 25 80 ± 7 17 ± 19 98 ± 43**
IL-8 377 ± 95 711 ± 102*** 1102 ± 810 6496 ± 2543***
IL-10 69 ± 43 85 ± 69 73 ± 17 240 ± 70***
*p < 0.05, **p < 0.001, ***p < 0.0001 versus survivors group.
Positive strong correlation of serum levels of IL-8 to APACHE II score (Spearman's rank ord r c rrelati n c eff cien )Figure 1
Positive strong correlation of serum levels of IL-8 to 
APACHE II score (Spearman's rank order correlation 
coefficient).
Negative correlation of BALF levels of IL-6, and IL6 receptor to P O2/FiO2 ratio (Spearman's rank order correlation c efficient)Figure 2
Negative correlation of BALF levels of IL-6, and IL6 receptor 
to PaO2/FiO2 ratio (Spearman's rank order correlation 
coefficient).Page 6 of 9
(page number not for citation purposes)
BMC Pulmonary Medicine 2004, 4:6 http://www.biomedcentral.com/1471-2466/4/6Patients of group A and group B had higher serum levels
of the inflammatory cytokine IL-8 compared to the
patients of group C, but neither serum nor BALF IL-8 lev-
els were predictive for ARDS development. In two studies,
Miller et al, [27] found that IL-8 in BAL at the beginning
of ARDS was highest in patients who died, and Donnelly
et al [28] found that IL-8 was highest in patients at risk for
ARDS who later developed ARDS. Unfortunately, subse-
quent studies have found that IL-8 does not predict out-
come either at the outset or during the course of ARDS
[5]). Meduri et al [16] found that all cytokines measured
remained high during the course of ARDS in patients who
died. The importance of considering anti-inflammatory
constituents of BALF is shown by Donnelly et al [28] who
found that patients with ARDS who died had significantly
lower initial concentrations of IL-10 in BAL than patients
who lived. Parson et al [29]) studied serial levels of IL-1ra
and IL-10 in patients who were identified as being at risk
for the development of ARDS. Initial IL-1ra levels were
significantly higher (p < 0.0001) in the patients than in
normal control subjects. Similarly, IL-10 levels were
increased in patients compared with normal control sub-
jects but did not predict the development of ARDS. Like
IL-1ra levels, initial IL-10 levels were significantly higher
(p = 0.005) in patients who died compared with survivors.
However, in other studies increased levels of IL-4, and IL-
10 in serum and/or BALF were found to have beneficial
effect in pre-ARDS patients [13,14]. Thus, the heterogene-
ity of patients in the various studies may be a reason for
the contradictive results reported earlier.
Prediction of outcome
Patients who died had significantly higher levels of IL-6,
IL-6r and IL-8 in BALF than those who finally survived,
while all mediators studied were significantly higher in
the serum of non-survivors. The rationale for analysis of
cytokine concentrations in BAL fluid is that inflammatory
cytokines, like IL-6 and IL-8 are known to be produced by
airway epithelial cells and activated pulmonary macro-
phages in response to a variety of infectious agents and
other triggers of airway inflammation [30]. During ARDS,
the alveolar epithelial-endothelial barrier is disrupted,
and cytokines produced in the lung are released into the
systemic circulation. This is believed to be a potential
mechanism for the development of systemic inflamma-
tory response syndrome [31,32]. The relationship
between circulatory and pulmonary cytokines levels and
outcome provides support to the hypothesis that poor
outcome in ARDS is related to a persistent inflammatory
process [30-33]. In addition, in agreement with our find-
ings, bronchoalveolar concentrations of the above
cytokines have been reported to be increased in patients
with or at risk for ARDS [33]. As demonstrated by Meduri
and co-workers, BAL fluid concentrations of IL-8 and IL-6
were significantly higher in nonsurvivors than in survivors
[31]. Increased BAL levels most likely indicate intrapul-
monary overproduction and not increased permeability
[33]. Therefore, determination of these selected inflam-
matory cytokines in BAL fluid in ARDS could be of
prognostic relevance [33,34]. Regarding serum levels,
patients at risk (groups B and C) who died had all mole-
cules significantly increased (Table 6), suggesting that
systemic inflammatory over-response in critically ill
patients may be destructive leading to multiple organ dys-
function and poor outcome. Serum levels of all the stud-
ied molecules were increased taking all patients together
(groups A+B+C, Table 4) or separate (Tables 5, 6, and 8)
that did not survive, suggesting that cytokinemia might
reflect the severity and extension of inflammation but is
not the only factor related to ARDS development. Interest-
ingly, only IL-8 and IL-10 both in BALF and serum were
higher in ARDS patients who died. These results are con-
sistent with those of Donnelly and coworkers, who found
elevated concentrations of IL-10 in BALF of 28 patients
with ARDS [35]. However, our results differ from those of
Armstrong and Millar, who found significantly lower con-
centrations of IL-10 in a small number group of patients
at risk for ARDS [36]. In addition, low concentrations of
IL-10 in BALF from patients with ARDS were found to be
associated with increased mortality [35,37]. In contrast,
all cytokines were elevated in those who died taking
together all the patients at risk (groups B and C). Regard-
ing the survival prediction, IL-8 and IL-10 showed the
higher serum positive predictive value (92 and 96%,
respectively), while IL-4 had the higher serum negative
predictive value and sensitivity, taking together all
patients.
Relation to severity of lung injury
Regarding the relation of the studied molecules and the
severity of lung injury, a negative correlation was found
between BALF IL-6, and IL-6r and PaO2/FiO2. The same
was true for serum IL-4 and PaO2/FiO2. All the studied
molecules in the serum were positively correlated with the
APACHE II score, as was BALF IL-8. It is probable that this
cytokine is closely related to the extension of tissue dam-
age and organ failure.
Conclusions
In conclusion, our data show that the predictive role of
most of the studied molecules both in serum and BALF for
ARDS development is valuable. In addition, almost all of
them are good predictors of outcome in these patients.
Further studies with greater number of patients with vari-
ous subgroups of ARDS as well as stricter grouping criteria
should be designed to investigate the complex network of
these molecules and their receptors in ARDS and their
value as predictive factors in these patients.Page 7 of 9
(page number not for citation purposes)
BMC Pulmonary Medicine 2004, 4:6 http://www.biomedcentral.com/1471-2466/4/6Competing interest
None declared.
Authors' contributions
DB conceived of the study, and participated in its design
and coordination and drafted the manuscript
MGA participated in the design of the study, carried out
immunoassays and drafted the manuscript
KMA carried out immunoassays and drafted the
manuscript
PA patients data and samples collection
IP patients data and samples collection
SA patients data and samples collection
GP Performed statistical analysis
AP patients data and samples collection
NK carried out RIA measurements
DP KMA carried out immunoassays and drafted the
manuscript
All authors read and approved the final manuscript
Acknowledgments
We thank Konstantinos Perisynakis for assisting in statistical analysis.
References
1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy
M, Legall JR, Morris A, Spragg R: The American-European Con-
sensus Conference onARDS Definitions, Mechanisms, Rele-
vant Outcomes, and Clinical Trial Coordination. Am J Respir
Crit Care Med 1994, 149:818-824.
2. Fowler AA, Hamman RF, Good JT, Benson KN, Baird M, Eberle DJ,
Petty TL, Hyers TM: Adult respiratory distress syndrome risk
with common predispositions. Ann Intern Med 1983, 98:593-597.
3. Rinaldo JE., Christman JW: Mechanisms and Mediators of the
adult respiratory distress syndrome. Clin Chest Med 1990,
11:621-629.
4. Pepe PE, Potkin RT, Reus DH, Hudson LD, Carrico CJ: Clinical pre-
dictors of the adult respiratory distress syndrome. Am J Surg
1982, 144:124-128.
5. Goodman RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA,
Maunder RJ, Kunkel SL, Walz A, Hudson LD, Martin TR: Inflamma-
tory cytokines in patients with persistence of the acute res-
piratory distress syndrome. Am J Respir Crit Care Med 1996,
154:602-611.
6. Bellingan GJ: The pathogenesis of ALI/ARDS. Thorax 2002,
57:540-6.
7. Tomashefski JF Jr: Pulmonary pathology of acute respiratory
distress syndrome. Clin Chest Med 2000, 21:435-466.
8. Meduri GU, Kanangat S, Stefan J, Tolley E, Schaberg D: Cytokines
IL-1beta, IL-6, and TNF-alpha enhance in vitro growth of
bacteria. Am J Respir Crit Care Med 1999, 160:961-967.
9. Park WY, Goodman RB, Steinberg KP, Ruzinski JT, Radella F 2nd, Park
DR, Pugin J, Skerrett SJ, Hudson LD, Martin TR: Cytokine balance
in the lungs of patients with acute respiratory distress
syndrome. Am J Respir Crit Care Med 2001, 164:1896-1903.
10. Tamura DY, Moore EE, Partrick DA, Johnson JL, Zallen G, Silliman
CC: IL-6 augments neutrophil cytotoxic potential via selec-
tive enhancement of elastase release. J Surg Res 1998, 76:91-94.
11. Kiehl MG, Ostermann H, Thomas M, Muller C, Cassens U, Kienast J:
Inflammatory mediators in bronchoalveolar lavage fluid and
plasma in leukocytopenic patients with septic shock-induced
acute respiratory distress syndrome. Crit Care Med 1998,
26:1194-1199.
12. Martin TR: Lung cytokines and ARDS: Roger S. Mitchell
Lecture. Chest 1999, 116:2S-8S.
13. Mulligan SM, Jones ML, Vaporciyan AA, Maureen CH, Ward PA: Pro-
tective effects of IL-4 and IL-10 against immune complex-
induced lung injury. J Immunol 1993, 151:5666-5674.
14. Van Laetherm JL, Eskinazi R, Louis H, Rickaert F, Robberecht P,
Devieve J: Multisystem production of interleukin 10 limits the
severity of acute pancreatitis in mice. Gut 1998, 43:408-413.
15. Headley AS, Tolley E, Meduri GU: Infections and the inflamma-
tory response in acute respiratory distress syndrome. Chest
1997, 111:1306-21.
16. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A:
Inflammatory cytokines in the BAL of patients with ARDS.
Persistent elevation over time predicts poor outcome. Chest
1995, 108:1303-14.
17. Schutte H, Lohmeyer J, Rosseau S, Ziegler S, Siebert C, Kielisch H,
Pralle H, Grimminger F, Morr H, Seeger W: Bronchoalveolar and
systemic cytokine profiles in patients with ARDS, severe
pneumonia and cardiogenic pulmonary oedema. Eur Respir J
1996, 9:1858-67.
18. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Cha-
noin MH, Wolff M, Spencer RC, Hemmer M: Prevalence of noso-
comial infection in intensive care units in Europe. Results of
the European Prevalence of Infection in Intensive Care
(EPIC) study. EPIC International Advisory Committee. JAMA
1995, 274:639-644.
19. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA,
Schein RM, Sibbald WJ: The ACCP/SCCM Consensus Confer-
ence Committee: American College of Chest Physicians/
Society of Critical Care Medicine Consensus Confer-
ence:Definitions for sepsis and organ failure and guidelines
for the use of innovative therapies in sepsis. Chest 1992,
101:1644-1655.
20. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a
severity of disease classification system. Crit Care Med 1985,
13:818-29.
21. Baldwin DR, Wise R, Andrews JM, Honeybourne D: Microlavage: a
technique for determining the volume of epithelial lining
fluid. Thorax 1991, 46:658-662.
22. Grassi J, Frobert Y, Pradelles P, Chercuitte F, Gruaz D, Dayer JM,
Poubelle PE: Production of monoclonal antibodies against IL-
1a and IL-1b: development of the two-enzyme immunomet-
ric assays (EIA) using acetylcholinesterase and their applica-
tion to biological media. J Immunol Meth 1989, 123:193-210.
23. Zweig MH, Campbell G: Receiver-operating characteristic
(ROC) plots: a fundamental evaluation tool in clinical
medicine. Clin Chem 1993, 39:561-77.
24. Mitchell RS: Lung cytokines and ARDS. Chest 1999, 116:2S-8S.
25. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R,
Leeper K: Persistent elevation of inflammatory cytokines pre-
dicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 lev-
els are consistent and efficient predictors of outcome over
time. Chest 1995, 107:1062-1073.
26. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP:
High circulating levels of interleukin-6 in patients with septic
shock: evolution during sepsis, prognostic value, and inter-
play with other cytokines. The Swiss-Dutch J5 Immunoglob-
ulin Study Group. Am J Med 1991, 91:23-29.
27. Miller EJ, Cohen AB, Nagao S, Griffith D, Maunder RJ, Martin TR,
Weiner-Kronish JP, Sticherling M, Christophers E, Matthay MA: Ele-
vated levels of NAP-1/interleukin-8 are present in the air-
spaces of patients with the adult respiratory distress
syndrome and are associated with increased mortality. Am
Rev Respir Dis 1992, 146:427-432.
28. Donnelly SC, Strieter RM, Reid PT, Kunkel SL, Burdick MD, Arm-
strong I, Mackenzie A, Haslett C: The association between mor-
tality rates and decreased concentrations of interleukin-10
and interleukin-1 receptor antagonist in the lung fluids ofPage 8 of 9
(page number not for citation purposes)
BMC Pulmonary Medicine 2004, 4:6 http://www.biomedcentral.com/1471-2466/4/6Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
patients with the adult respiratory distress syndrome. Ann
Intern Med 1996, 125:191-196.
29. Parsons PE, Moss M, Vannice JL, Moore EE, Moore FA, Repine JE: Cir-
culating IL-1ra and IL-10 levels are increased but do not pre-
dict the development of acute respiratory distress syndrome
in at risk patients. Am J Respir Crit Care Med 1997, 155:1469-1473.
30. Shelhamer JH, Levine SJ, Wu T, Jacoby DB, Kaliner MA, Rennard SI:
Airway inflammation. Ann Intern Med 1995, 123:288-304.
31. Agouridakis P, Kyriakou D, Alexandrakis MG, Prekates A, Perisinakis
K, Karkavitsas N, Bouros D: The predictive role of serum and
bronchoalveolar lavage cytokines and adhesion molecules
for acute respiratory distress syndrome development and
outcome. Respir Res 2002, 23(3(1)):25.
32. Agouridakis P, Kyriakou D, Alexandrakis MG, Persinakis K, Karkavit-
sas N, Bouros D: Association between increased levels of IL-2
and IL-15 and outcome in patients with early acute respira-
tory distress syndrome. Eur J Clin Invest 2002, 32:862-867.
33. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A:
Inflammatory cytokines in the BAL of patients with ARDS.
Chest 1995, 108:1303-1314.
34. Kiehl MG, Ostermann H, Thomas M, Muller T, Cassens U, Kienast J:
Inflammatory mediators in bronchoalveolar lavage fluid and
plasma in leukocytopenic patients with septic shock-induced
acite respiratory distress syndrome. Crit Care Med 1998,
26:1194-1198.
35. Donnelly SC, Strieter RM, Reid PT, Kunkel SL, Burdick MD, Arm-
strong I, Mackenzie A, Haslett C: The association between mor-
tality rates and decreased concentrations of IL-10 and
interleukin-1 receptor antagonist in the lung fluids of
patients with the adult respiratory distress syndrome. Ann
Intern Med 1996, 125:191-196.
36. Armstrong L, Millar AB: Relative production of tumour necrosis
factor alpha and interleukin in adult respiratory distress
syndrome. Thorax 1997, 52:442-446.
37. Park WY, Goodman RB, Steinberg KP, Ruzinski JT, Radella F 2nd, Park
DR, Pugin J, Skerrett SJ, Hudson LD, Martin TR: Cytokine balance
in the lungs of patients with acute respiratory distress
syndrome. Am J Respir Crit Care Med 2001, 164:1896-1903.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2466/4/6/prepubPage 9 of 9
(page number not for citation purposes)
